Equities Analysts Issue Forecasts for Exelixis Q1 Earnings

Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at Zacks Research reduced their Q1 2026 earnings per share estimates for shares of Exelixis in a research note issued on Tuesday, October 7th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $0.48 per share for the quarter, down from their previous forecast of $0.54. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Zacks Research also issued estimates for Exelixis’ Q2 2026 earnings at $0.52 EPS, Q3 2026 earnings at $0.60 EPS, Q1 2027 earnings at $0.63 EPS and Q2 2027 earnings at $0.74 EPS.

Other equities analysts have also recently issued research reports about the company. Royal Bank Of Canada lowered their target price on Exelixis from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Tuesday, July 29th. Wall Street Zen raised Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. Stephens raised Exelixis from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $29.00 to $60.00 in a research note on Tuesday, June 24th. Jefferies Financial Group set a $50.00 price target on Exelixis and gave the company a “buy” rating in a research note on Tuesday, June 24th. Finally, Guggenheim reissued a “buy” rating and issued a $45.00 price target on shares of Exelixis in a research note on Tuesday, July 29th. Fifteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $44.42.

Exelixis Price Performance

NASDAQ:EXEL opened at $38.57 on Thursday. Exelixis has a fifty-two week low of $25.17 and a fifty-two week high of $49.62. The stock’s 50-day moving average is $38.62 and its two-hundred day moving average is $39.91. The stock has a market cap of $10.38 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.80 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company had revenue of $568.26 million for the quarter, compared to analysts’ expectations of $574.36 million. During the same quarter in the previous year, the business posted $0.84 EPS. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Exelixis

A number of large investors have recently added to or reduced their stakes in EXEL. Nuveen LLC bought a new stake in Exelixis during the first quarter worth approximately $123,310,000. AQR Capital Management LLC lifted its holdings in shares of Exelixis by 73.8% during the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after buying an additional 2,926,884 shares during the last quarter. Norges Bank acquired a new position in shares of Exelixis during the second quarter worth approximately $122,099,000. Qube Research & Technologies Ltd lifted its holdings in shares of Exelixis by 120.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock worth $134,306,000 after buying an additional 1,665,110 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Exelixis by 40.2% during the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after buying an additional 1,596,948 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.